<DOC>
	<DOC>NCT01069094</DOC>
	<brief_summary>A study of 3 doses of Progenta versus placebo versus Lucron Depot for treatment of leiomyomata.</brief_summary>
	<brief_title>A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata</brief_title>
	<detailed_description>Three doses of Progenta (CDB4124 - 12.5, 25, 50 mg) versus placebo versus Lucron Depot (leuprolide acetate for depot suspension) was initiated in females with symptomatic leiomyomata. A single dose PK visit was conducted only for subjects randomized to the Progenta arm, between screening and visit 1. A second PK assessment was conducted at Visit 3 (one month on drug) to collect steady state data. Treatment period lasted for 3 months.</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Had at least one leiomyomata lesion that was identifiable and measurable by transvaginal ultrasound. Had a regular or steady menstrual cycle lasting from 24 to 36 days. Postmenopausal Subject with documented endometriosis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Uterine fibroids</keyword>
</DOC>